Compile Data Set for Download or QSAR
Report error Found 336 Enz. Inhib. hit(s) with all data for entry = 12986
TargetComplement factor D(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM747772(2-(2-((7-(3-(aminomethyl)phenyl)-5-(hydroxymethyl)...)
Affinity DataIC50: 1.00E+3nMAssay Description:Specifically, the compounds were dissolved in a stock solution of DMSO at 10.0 or 100 mM. A portion of this stock solution was added to assay buffer ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/7/2025
Entry Details
US Patent

TargetComplement factor D(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM747771(2,2'-((((7-(3-(aminomethyl)phenyl)benzofuran-2,5-d...)
Affinity DataIC50: 1.00E+3nMAssay Description:Specifically, the compounds were dissolved in a stock solution of DMSO at 10.0 or 100 mM. A portion of this stock solution was added to assay buffer ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/7/2025
Entry Details
US Patent

TargetComplement factor D(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM747972(2-(2-(5-(3-(aminomethyl)phenyl)benzofuran-3-carbox...)
Affinity DataIC50: 1.00E+3nMAssay Description:Specifically, the compounds were dissolved in a stock solution of DMSO at 10.0 or 100 mM. A portion of this stock solution was added to assay buffer ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/7/2025
Entry Details
US Patent

TargetComplement factor D(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM747970(2-(2-((5-(3-(aminomethyl)phenyl)benzofuran-3-yl)me...)
Affinity DataIC50: 1.00E+3nMAssay Description:Specifically, the compounds were dissolved in a stock solution of DMSO at 10.0 or 100 mM. A portion of this stock solution was added to assay buffer ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/7/2025
Entry Details
US Patent

TargetComplement factor D(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM747964(2-(2-((7-(3-(aminomethyl)phenyl)benzo[b]thiophen-2...)
Affinity DataIC50: 1.00E+3nMAssay Description:Specifically, the compounds were dissolved in a stock solution of DMSO at 10.0 or 100 mM. A portion of this stock solution was added to assay buffer ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/7/2025
Entry Details
US Patent

TargetComplement factor D(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM747963(ethyl 2-(2-((7-(3-(aminomethyl)phenyl)-5-fluoroben...)
Affinity DataIC50: 1.00E+3nMAssay Description:Specifically, the compounds were dissolved in a stock solution of DMSO at 10.0 or 100 mM. A portion of this stock solution was added to assay buffer ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/7/2025
Entry Details
US Patent

TargetComplement factor D(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM747961(2-(2-((7-(3-(aminomethyl)phenyl)-5-((2-(2-ethoxy-2...)
Affinity DataIC50: 1.00E+3nMAssay Description:Specifically, the compounds were dissolved in a stock solution of DMSO at 10.0 or 100 mM. A portion of this stock solution was added to assay buffer ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/7/2025
Entry Details
US Patent

TargetComplement factor D(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM747979(2-(2-((5-(3-(aminomethyl)-2-fluorophenyl)benzofura...)
Affinity DataIC50: 1.00E+3nMAssay Description:Specifically, the compounds were dissolved in a stock solution of DMSO at 10.0 or 100 mM. A portion of this stock solution was added to assay buffer ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/7/2025
Entry Details
US Patent

TargetComplement factor D(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM747978(2-(2-((3-(3-(aminomethyl)phenyl)benzofuran-5-yl)me...)
Affinity DataIC50: 1.00E+3nMAssay Description:Specifically, the compounds were dissolved in a stock solution of DMSO at 10.0 or 100 mM. A portion of this stock solution was added to assay buffer ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/7/2025
Entry Details
US Patent

TargetComplement factor D(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM747977(2-(2-((7-(3-(aminomethyl)phenyl)-2-((2-(2-(tert-bu...)
Affinity DataIC50: 1.00E+3nMAssay Description:Specifically, the compounds were dissolved in a stock solution of DMSO at 10.0 or 100 mM. A portion of this stock solution was added to assay buffer ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/7/2025
Entry Details
US Patent

TargetComplement factor D(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM747976(2-(2-((5-(3-(aminomethyl)phenyl)benzofuran-3-yl)me...)
Affinity DataIC50: 1.00E+3nMAssay Description:Specifically, the compounds were dissolved in a stock solution of DMSO at 10.0 or 100 mM. A portion of this stock solution was added to assay buffer ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/7/2025
Entry Details
US Patent

TargetComplement factor D(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM747975(2-(2-((7-(3-(aminomethyl)phenyl)-5-(((cyclopropylm...)
Affinity DataIC50: 1.00E+3nMAssay Description:Specifically, the compounds were dissolved in a stock solution of DMSO at 10.0 or 100 mM. A portion of this stock solution was added to assay buffer ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/7/2025
Entry Details
US Patent

TargetComplement factor D(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM747974(2-(2-((7-(3-(aminomethyl)phenyl)-5-(methoxycarbony...)
Affinity DataIC50: 1.00E+3nMAssay Description:Specifically, the compounds were dissolved in a stock solution of DMSO at 10.0 or 100 mM. A portion of this stock solution was added to assay buffer ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/7/2025
Entry Details
US Patent

TargetComplement factor D(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM747973(2-(2-((5-(3-(aminomethyl)-2-fluorophenyl)benzofura...)
Affinity DataIC50: 1.00E+3nMAssay Description:Specifically, the compounds were dissolved in a stock solution of DMSO at 10.0 or 100 mM. A portion of this stock solution was added to assay buffer ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/7/2025
Entry Details
US Patent

TargetComplement factor D(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM747838(2-(2-((7-(3-(aminomethyl)phenyl)-2-(2-(2-(carboxym...)
Affinity DataIC50: 1.00E+3nMAssay Description:Specifically, the compounds were dissolved in a stock solution of DMSO at 10.0 or 100 mM. A portion of this stock solution was added to assay buffer ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/7/2025
Entry Details
US Patent

TargetComplement factor D(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM747829(2-(3-((5-(3-(aminomethyl)-2-fluorophenyl)benzofura...)
Affinity DataIC50: 1.00E+3nMAssay Description:Specifically, the compounds were dissolved in a stock solution of DMSO at 10.0 or 100 mM. A portion of this stock solution was added to assay buffer ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/7/2025
Entry Details
US Patent

TargetComplement factor D(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM747821(2-(2-((7-(3-(aminomethyl)phenyl)benzofuran-2-yl)me...)
Affinity DataIC50: 1.00E+3nMAssay Description:Specifically, the compounds were dissolved in a stock solution of DMSO at 10.0 or 100 mM. A portion of this stock solution was added to assay buffer ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/7/2025
Entry Details
US Patent

TargetComplement factor D(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM747779(2-(2-((5-(3-(aminomethyl)-2-fluorophenyl)benzofura...)
Affinity DataIC50: 1.00E+3nMAssay Description:Specifically, the compounds were dissolved in a stock solution of DMSO at 10.0 or 100 mM. A portion of this stock solution was added to assay buffer ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/7/2025
Entry Details
US Patent

TargetComplement factor D(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM747775(2-(2-((7-(3-(aminomethyl)phenyl)-5-(phenoxymethyl)...)
Affinity DataIC50: 1.00E+3nMAssay Description:Specifically, the compounds were dissolved in a stock solution of DMSO at 10.0 or 100 mM. A portion of this stock solution was added to assay buffer ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/7/2025
Entry Details
US Patent

TargetComplement factor D(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM747774(2,2'-((((7-(3-(aminomethyl)-2-fluorophenyl)benzofu...)
Affinity DataIC50: 1.00E+3nMAssay Description:Specifically, the compounds were dissolved in a stock solution of DMSO at 10.0 or 100 mM. A portion of this stock solution was added to assay buffer ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/7/2025
Entry Details
US Patent

TargetComplement factor D(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM747773(2-(2-((5-(3-(aminomethyl)phenyl)benzofuran-3-yl)me...)
Affinity DataIC50: 1.00E+3nMAssay Description:Specifically, the compounds were dissolved in a stock solution of DMSO at 10.0 or 100 mM. A portion of this stock solution was added to assay buffer ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/7/2025
Entry Details
US Patent

TargetComplement factor D(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM747896(2-(2-((5-(3-(aminomethyl)-5-fluorophenyl)benzofura...)
Affinity DataIC50: 1.00E+3nMAssay Description:Specifically, the compounds were dissolved in a stock solution of DMSO at 10.0 or 100 mM. A portion of this stock solution was added to assay buffer ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/7/2025
Entry Details
US Patent

TargetComplement factor D(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM747894(2-(2-((5-(3-(aminomethyl)phenyl)benzofuran-3-yl)me...)
Affinity DataIC50: 1.00E+3nMAssay Description:Specifically, the compounds were dissolved in a stock solution of DMSO at 10.0 or 100 mM. A portion of this stock solution was added to assay buffer ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/7/2025
Entry Details
US Patent

TargetComplement factor D(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM747871(2-(2-((5,7-bis(3-(aminomethyl)phenyl)benzofuran-2-...)
Affinity DataIC50: 1.00E+3nMAssay Description:Specifically, the compounds were dissolved in a stock solution of DMSO at 10.0 or 100 mM. A portion of this stock solution was added to assay buffer ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/7/2025
Entry Details
US Patent

TargetComplement factor D(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM747869(2-(2-((5-(3-(aminomethyl)phenyl)benzofuran-3-yl)me...)
Affinity DataIC50: 1.00E+3nMAssay Description:Specifically, the compounds were dissolved in a stock solution of DMSO at 10.0 or 100 mM. A portion of this stock solution was added to assay buffer ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/7/2025
Entry Details
US Patent

TargetComplement factor D(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM748004(2-(2-((5-(2-(aminomethyl)-3-fluoropyridin-4-yl)ben...)
Affinity DataIC50: 1.00E+3nMAssay Description:Specifically, the compounds were dissolved in a stock solution of DMSO at 10.0 or 100 mM. A portion of this stock solution was added to assay buffer ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/7/2025
Entry Details
US Patent

TargetComplement factor D(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM748003(2-(2-((5-(3-(aminomethyl)phenyl)-2-(tert-butoxycar...)
Affinity DataIC50: 1.00E+3nMAssay Description:Specifically, the compounds were dissolved in a stock solution of DMSO at 10.0 or 100 mM. A portion of this stock solution was added to assay buffer ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/7/2025
Entry Details
US Patent

TargetComplement factor D(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM748002(2-(2-((5-(3-(aminomethyl)phenyl)-6-methoxybenzofur...)
Affinity DataIC50: 1.00E+3nMAssay Description:Specifically, the compounds were dissolved in a stock solution of DMSO at 10.0 or 100 mM. A portion of this stock solution was added to assay buffer ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/7/2025
Entry Details
US Patent

TargetComplement factor D(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM748000(2-(2-((5-(3-(aminomethyl)phenyl)benzofuran-3-yl)me...)
Affinity DataIC50: 1.00E+3nMAssay Description:Specifically, the compounds were dissolved in a stock solution of DMSO at 10.0 or 100 mM. A portion of this stock solution was added to assay buffer ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/7/2025
Entry Details
US Patent

TargetComplement factor D(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM747999(2-(2-((5-(3-(aminomethyl)phenyl)benzo[b]thiophen-3...)
Affinity DataIC50: 1.00E+3nMAssay Description:Specifically, the compounds were dissolved in a stock solution of DMSO at 10.0 or 100 mM. A portion of this stock solution was added to assay buffer ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/7/2025
Entry Details
US Patent

TargetComplement factor D(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM747998(2-(2-((7-(3-(aminomethyl)phenyl)-5-((cyclopropylme...)
Affinity DataIC50: 1.00E+3nMAssay Description:Specifically, the compounds were dissolved in a stock solution of DMSO at 10.0 or 100 mM. A portion of this stock solution was added to assay buffer ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/7/2025
Entry Details
US Patent

TargetComplement factor D(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM747997(2-(2-((5-(3-(aminomethyl)-2-fluorophenyl)benzofura...)
Affinity DataIC50: 1.00E+3nMAssay Description:Specifically, the compounds were dissolved in a stock solution of DMSO at 10.0 or 100 mM. A portion of this stock solution was added to assay buffer ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/7/2025
Entry Details
US Patent

TargetComplement factor D(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM748012(2-(4-amino-2-((5-(3-(aminomethyl)phenyl)benzofuran...)
Affinity DataIC50: 1.00E+3nMAssay Description:Specifically, the compounds were dissolved in a stock solution of DMSO at 10.0 or 100 mM. A portion of this stock solution was added to assay buffer ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/7/2025
Entry Details
US Patent

TargetComplement factor D(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM748011(5-(3-(aminomethyl)phenyl)-3-((2-(carboxymethyl)-5-...)
Affinity DataIC50: 1.00E+3nMAssay Description:Specifically, the compounds were dissolved in a stock solution of DMSO at 10.0 or 100 mM. A portion of this stock solution was added to assay buffer ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/7/2025
Entry Details
US Patent

TargetComplement factor D(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM748010((S)-2-(2-((5-(3-(1-amino-2-hydroxyethyl)phenyl)ben...)
Affinity DataIC50: 1.00E+3nMAssay Description:Specifically, the compounds were dissolved in a stock solution of DMSO at 10.0 or 100 mM. A portion of this stock solution was added to assay buffer ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/7/2025
Entry Details
US Patent

TargetComplement factor D(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM748009(2-(2-((5-(3-(aminomethyl)phenyl)benzofuran-3-yl)me...)
Affinity DataIC50: 1.00E+3nMAssay Description:Specifically, the compounds were dissolved in a stock solution of DMSO at 10.0 or 100 mM. A portion of this stock solution was added to assay buffer ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/7/2025
Entry Details
US Patent

TargetComplement factor D(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM748007(2-(2-((5-(3-(aminomethyl)phenyl)benzofuran-3-yl)me...)
Affinity DataIC50: 1.00E+3nMAssay Description:Specifically, the compounds were dissolved in a stock solution of DMSO at 10.0 or 100 mM. A portion of this stock solution was added to assay buffer ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/7/2025
Entry Details
US Patent

TargetComplement factor D(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM748006(2-(2-((5-(3-(aminomethyl)phenyl)-7-((dimethylamino...)
Affinity DataIC50: 1.00E+3nMAssay Description:Specifically, the compounds were dissolved in a stock solution of DMSO at 10.0 or 100 mM. A portion of this stock solution was added to assay buffer ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/7/2025
Entry Details
US Patent

TargetComplement factor D(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM747988(2-((5-(3-(aminomethyl)phenyl)benzofuran-3-yl)metho...)
Affinity DataIC50: 1.00E+3nMAssay Description:Specifically, the compounds were dissolved in a stock solution of DMSO at 10.0 or 100 mM. A portion of this stock solution was added to assay buffer ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/7/2025
Entry Details
US Patent

TargetComplement factor D(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM747987(2-(3-((7-(3-(aminomethyl)phenyl)-2-((2-(carboxymet...)
Affinity DataIC50: 1.00E+3nMAssay Description:Specifically, the compounds were dissolved in a stock solution of DMSO at 10.0 or 100 mM. A portion of this stock solution was added to assay buffer ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/7/2025
Entry Details
US Patent

TargetComplement factor D(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM747986(2-(2-((4-(3-(aminomethyl)phenyl)benzofuran-2-yl)me...)
Affinity DataIC50: 1.00E+3nMAssay Description:Specifically, the compounds were dissolved in a stock solution of DMSO at 10.0 or 100 mM. A portion of this stock solution was added to assay buffer ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/7/2025
Entry Details
US Patent

TargetComplement factor D(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM747985(2-(2-((5-(3-(aminomethyl)phenyl)benzofuran-3-yl)me...)
Affinity DataIC50: 1.00E+3nMAssay Description:Specifically, the compounds were dissolved in a stock solution of DMSO at 10.0 or 100 mM. A portion of this stock solution was added to assay buffer ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/7/2025
Entry Details
US Patent

TargetComplement factor D(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM747984(3-(2-((7-(3-(aminomethyl)phenyl)-2-((2-(carboxymet...)
Affinity DataIC50: 1.00E+3nMAssay Description:Specifically, the compounds were dissolved in a stock solution of DMSO at 10.0 or 100 mM. A portion of this stock solution was added to assay buffer ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/7/2025
Entry Details
US Patent

TargetComplement factor D(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM747983(2,2'-((((7-(2-(aminomethyl)pyridin-4-yl)benzofuran...)
Affinity DataIC50: 1.00E+3nMAssay Description:Specifically, the compounds were dissolved in a stock solution of DMSO at 10.0 or 100 mM. A portion of this stock solution was added to assay buffer ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/7/2025
Entry Details
US Patent

TargetComplement factor D(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM747982(2-(2-((5-(3-(aminomethyl)-2-fluorophenyl)benzofura...)
Affinity DataIC50: 1.00E+3nMAssay Description:Specifically, the compounds were dissolved in a stock solution of DMSO at 10.0 or 100 mM. A portion of this stock solution was added to assay buffer ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/7/2025
Entry Details
US Patent

TargetComplement factor D(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM747981(2-(2-(5-(3-(aminomethyl)phenyl)-1H-pyrrolo[3,2-b]p...)
Affinity DataIC50: 1.00E+3nMAssay Description:Specifically, the compounds were dissolved in a stock solution of DMSO at 10.0 or 100 mM. A portion of this stock solution was added to assay buffer ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/7/2025
Entry Details
US Patent

TargetComplement factor D(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM747996(2-(2-((5-(3-(aminomethyl)phenyl)-7-methoxybenzofur...)
Affinity DataIC50: 1.00E+3nMAssay Description:Specifically, the compounds were dissolved in a stock solution of DMSO at 10.0 or 100 mM. A portion of this stock solution was added to assay buffer ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/7/2025
Entry Details
US Patent

TargetComplement factor D(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM747995(2-(2-((7-(3-(aminomethyl)phenyl)-5-fluorobenzofura...)
Affinity DataIC50: 1.00E+3nMAssay Description:Specifically, the compounds were dissolved in a stock solution of DMSO at 10.0 or 100 mM. A portion of this stock solution was added to assay buffer ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/7/2025
Entry Details
US Patent

TargetComplement factor D(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM747993(2-(2-((5-(3-(aminomethyl)phenyl)-7-methylbenzofura...)
Affinity DataIC50: 1.00E+3nMAssay Description:Specifically, the compounds were dissolved in a stock solution of DMSO at 10.0 or 100 mM. A portion of this stock solution was added to assay buffer ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/7/2025
Entry Details
US Patent

TargetComplement factor D(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM747990(2-(2-((7-(3-(aminomethyl)phenyl)naphthalen-1-yl)me...)
Affinity DataIC50: 1.00E+3nMAssay Description:Specifically, the compounds were dissolved in a stock solution of DMSO at 10.0 or 100 mM. A portion of this stock solution was added to assay buffer ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/7/2025
Entry Details
US Patent

Displayed 1 to 50 (of 336 total ) | Next | Last >>
Jump to: